Immunoglobulin AMG Anti Natural Disaccharide Octyl - Leprosy IDRI Diagnostic (NDO-LID) Serologic Test for Leprosy Diagnosis: a Pilot Study


Published: 29 March 2019
Abstract Views: 1652
PDF: 604
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Bayu Bijaksana Rumondor Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Anisha Callista Prakoeswa Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Meva Nareza Trianita Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • I. Iswahyudi Leprosy Study Group, Institute of Tropical Diseases, Universitas Airlangga, Surabaya, Indonesia.
  • Nanny Herwanto Leprosy Study Group, Institute of Tropical Diseases, Universitas Airlangga, Surabaya, Indonesia.
  • M. Yulianto Listiawan Leprosy Study Group, Institute of Tropical Diseases, Universitas Airlangga, Surabaya, Indonesia.
  • Indropo Agusni Department of Dermatology and Venereology, Universitas Airlangga, Dr. Soetomo Teaching Hospital, Surabaya, Indonesia.
  • Shinzo Izumi Leprosy Study Group, Institute of Tropical Diseases, Universitas Airlangga, Surabaya, Indonesia.
  • Malcom Duthie Infectious Disease Research Institute, Seattle, United States.
  • Cita Rosita Sigit Prakoeswa Department of Dermatology and Venereology, Universitas Airlangga, Dr. Soetomo Teaching Hospital, Surabaya, Indonesia.

Leprosy remains a public health problem in Indonesia. Diagnostic tools have been developed in order to aid early diagnosis and prompt treatment. Phenolic glycolipid (PGL)-1 has been considered as a good candidate for leprosy diagnosis but has been found to have several limitations. More recently, the conjugation between natural disaccharide octyl (NDO) and leprosy IDRI diagnostic (LID)-1, known as NDO-LID, shows great promise because of its high specificity and sensitivity and its ability to detect leprosy before any clinical signs are present. The test incorporates the detection of IgM antibodies towards NDO and IgG antibodies towards LID-1. This study aimed to show the profile of IgM, IgG, and IgAMG antibody titers against NDO-LID to further discover its diagnostic potential. Sera from eight new leprosy patients from Surabaya, Indonesia were evaluated using ELISA detecting levels of IgG, IgM and IgAMG antibodies against NDO-LID antigen. Skin slit biopsy was also taken for smear and histopathology test. This study shows that the titer levels IgAMG anti NDO-LID were consistent with the results from smear and were consistently higher compared to IgM or IgG titer alone. IgAMG might have the potential to improve the sensitivity of NDO-LID serologic tests but further investigation is needed.


Rumondor, B. B., Prakoeswa, A. C., Trianita, M. N., Iswahyudi, I., Herwanto, N., Listiawan, M. Y., Agusni, I., Izumi, S., Duthie, M., & Sigit Prakoeswa, C. R. (2019). Immunoglobulin AMG Anti Natural Disaccharide Octyl - Leprosy IDRI Diagnostic (NDO-LID) Serologic Test for Leprosy Diagnosis: a Pilot Study. Dermatology Reports, 11(s1). https://doi.org/10.4081/dr.2019.8025

Downloads

Download data is not yet available.

Citations